ProMIS Neurosciences, Inc has announced that numerous antibodies against toxic oligomers of alpha-synuclein, implicated in Parkinson’s disease (PD) have begun the final stage of discovery. Hundreds of monoclonal antibodies were generated against predicted disease-specific epitopes and validation and prioritization to select therapeutic candidates with a highly selective profile for these targets.
Parkinson's disease is characterized by loss of dopaminergic neurons in the midbrain and inclusion bodies, or Lewy bodies, which consist mainly of aggregates of alpha-synuclein. Recent evidence suggests that oligomers of alpha-synuclein are the toxic form, rather than monomers or insoluble fibrils. Aggregated, toxic alpha-synuclein can also propagate in a prion-like manner.
"(Our) proprietary discovery platform consists of two stages" said Dr. Neil Cashman, ProMIS Chief Scientific Officer. "The first stage involves predicting novel epitope targets and using these to generate large numbers of candidate antibodies. The second stage is to validate selectivity, functional activity, and select the best leads. We are very pleased with our progress so far in identifying epitopes displayed by the toxic oligomers that are the root cause of disease and are moving into the validation and selection phase with these targets."
"The outstanding efficiency of our unique discovery platform is exemplified by the success of our lead Alzheimer's disease (AD) program which led to the rapid identification and validation of PMN310, our therapeutic antibody candidate that is selective for toxic oligomers of amyloid-ß, a root cause of AD," said Johanne Kaplan, ProMIS Chief Development Officer. "We are applying a similar, rigorous evaluation process to the numerous antibody candidates against toxic oligomers of alpha-synuclein and anticipate generating the scientific data required to select the best lead(s) over the coming months."Next Story